Affordable Access

Access to the full text

The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics

Authors
  • Chan, Hiu Ting1
  • Chin, Yoon Ming1
  • Low, Siew-Kee1
  • 1 Japanese Foundation for Cancer Research, Cancer Precision Medicine Center, Tokyo, Japan , Tokyo (Japan)
Type
Published Article
Journal
Oncology and Therapy
Publisher
Springer Healthcare
Publication Date
Jan 04, 2019
Volume
7
Issue
1
Pages
1–32
Identifiers
DOI: 10.1007/s40487-018-0090-6
Source
Springer Nature
Keywords
License
Yellow

Abstract

Cancer pharmacogenomics is the science concerned with understanding genetic alterations and its effects on the pharmacokinetics and pharmacodynamics of anti-cancer drugs, with the aim to provide cancer patients with the precise medication that will achieve a good response and cause low/no incidence of adverse events. Advances in biotechnology and bioinformatics have enabled genomic research to evolve from the evaluation of alterations at the single-gene level to studies on the whole-genome scale using large-scale genotyping and next generation sequencing techniques. International collaborative efforts have resulted in the construction of databases to curate the identified genetic alterations that are clinically significant, and these are currently utilized in clinical sequencing and liquid biopsy screening/monitoring. Furthermore, countless clinical studies have accumulated sufficient evidence to match cancer patients to therapies by utilizing the information of clinical-relevant alterations. In this review we summarize the importance of germline alterations that act as predictive biomarkers for drug-induced toxicity and drug response as well as somatic mutations in cancer cells that function as drug targets. The integration of genomics into the medical field has transformed the era of cancer therapy from one-size-fits-all to cancer precision medicine.

Report this publication

Statistics

Seen <100 times